


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,




wherein

R¹ is hydrogen,


R² is hydrogen or C₁₋₂₀-alkyl,

R³ is hydrogen, C₁₋₂₀-alkyl, C₄₋₈-cycloalkyl, C₅₋₈-cycloalkylenyl, aryl, aromatic or non aromatic heterocycle, C₁₋₂₀-alkoxy, or a group of formula -W-R⁸.

R^{3a} is hydrogen, C₁₋₂₀-alkyl or a group of formula:



or NR³R^{3a} is a group of formula



R⁴ is hydrogen,

R⁵ is hydrogen; nitro; halogen; azido; cyano; -S-C₁₋₄-alkyl; -SO-C₁₋₄-alkyl; -SO₂-C₁₋₄-alkyl; -SONH₂; C₁₋₂₀-alkyl unsubstituted or substituted by halogen; or C₁₋₂₀-alkoxy unsubstituted or substituted by halogen,

R⁶ is hydrogen, C₁₋₂₀-alkyl or halogen,

R⁷ is hydrogen, C₁₋₂₀-alkyl or halogen, W is C₁₋₁₂-alkylene, -NH- or -NHC(=O)-,

X is O, S or NH,

Y is O, S, $-\text{CR}^{12}\text{R}^{13}-$, NR^{14} or $-\text{C}(=\text{O})-$

R^8 is aryl or heterocycle,

R^9 , R^{10} , R^{10a} and R^{11} are independently selected from hydrogen, C_{1-4} -alkyl, halogen, hydroxy or methoxycarbonyl,

or R^{10} and R^{10a} together form a C_{3-6} -alkylene,

R^{12} is hydrogen, C_{1-4} -alkyl, halogen or hydroxy,

R^{13} is hydrogen,

or $\text{CR}^{12}\text{R}^{13}$ is dioxolanyl,

R^{14} is aryl, heterocycle or a group of formula $-\text{V}-\text{R}^{15}$,

V is C_{1-12} -alkylene,


R^{15} is aryl or heterocycle,

m is 1 to 4,

n is 0 or 1, and at least one of R^5 , R^6 or R^7 is different from hydrogen when R^2 is hydrogen,

R^3 is H or 2, 6-diisopropylphenyl, and R^{3a} is H.

2. (currently amended) A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,




wherein

R^1 is hydrogen,


R^2 is hydrogen or C_{1-4} -alkyl,

R^3 is hydrogen; C_{1-6} -alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylamino; C_{5-7} -cycloalkyl; (hydroxymethyl) cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C_{1-4} -alkyl, hydroxy, methoxy, nitro, methylsulfonyl, trifluoromethylthio or pyridinylalkyl; pyridinyl unsubstituted or substituted by methoxy; triazolyl; C_{1-4} -alkoxy; or a group of formula $-\text{W}-\text{R}^8$,

R^{3a} is hydrogen, C₁₋₄-alkyl or a group of formula



or NR³R^{3a} is piperidinyl unsubstituted or substituted by hydroxy; thiomorpholinyl; thiazolidinyl unsubstituted or substituted by C₁₋₄-alkoxycarbonyl; 2,5-dihydro-1H-pyrrol-1-yl; 1,4-dioxo-8-azaspiro [4.5] dec-8-yl; 4-oxooctahydro-1 (2H)-quinolinyl; or a group of formula



R⁴ is hydrogen,

R⁵ is hydrogen; nitro; halogen; C₁₋₄-alkyl, unsubstituted or substituted by halogen; or C₁₋₄-alkoxy unsubstituted or substituted by halogen,

R⁶ is hydrogen, C₁₋₆-alkyl or halogen,

R⁷ is hydrogen, methyl or halogen,

W is C₁₋₄-alkylene unsubstituted or substituted by halogen, hydroxy, C₁₋₄-alkyl or alkoxy; -NH-; or -NHC(=O)-,

R⁸ is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C₁₋₄-allyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluoromethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl; pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl,

R¹⁴ is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, C₁₋₄-alkyl; or a group of formula -V-R¹⁵,


V is unsubstituted C₁₋₄-alkylene,

R¹⁵ is phenyl or morpholinyl,

m is 1 to 4,

and at least one of R⁵, R⁶ ~~or~~ and R⁷ is different from hydrogen when R² is hydrogen, R³ is H or 2,6-diisopropylphenyl, and R^{3a} is H.

3. (currently amended) A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



wherein

R¹ is hydrogen,

R² is hydrogen, methyl or ethyl,

R³ is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, 1-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dimethylamino)propyl, 6-(hydroxymethyl)cyclohex-3-en-1-yl, 3-hydroxyphenyl, 3-fluorophenyl, 3-(2-pyridin-2-ylethyl) phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro-6-fluorobenzyl, 2-[(trifluoromethyl) thio] benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, [4-bromophenyl]amino, pyridin-3-yl, 6-methoxypyridin-3-yl, 4H-1,2,4-triazol-3-yl, pyridin-4-ylmethyl, [5-methyl-2-furyl)methyl, 3-(1H-pyrazol-1-yl)propyl, 2-morpholin-4-ylethyl, 2-((3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl, 2-(2-methylpiperidin-1-yl)ethyl, 3,4-dihydro-1H-isochromen-1-ylmethy, methoxy, (4-pyridinyl carbonyl)amino or 4,5-dihydro-1H-imidazol-2-ylamino,

R^{3a} is hydrogen, methyl or tetrahydrofuran-2-ylmethyl,

or NR³N^{3a} is 4R-pyridin-2-ylpiperazin-1-yl, 4-(3-methylphenyl)piperazin-1-yl, 4-(4-hydroxyphenyl)piperazin-1-yl, 4-(2-phenylethyl)piperazin-1-yl, 4-(2-morpholin-4-ylethyl)piperazin-1-yl, 3-hydroxypiperidin-1-yl, thiomorpholin-4-yl, 4-methoxycarbonyl-1,3-thiazolidin-3-yl, 2,5-dihydro-1H-pyrrol-1-yl, 1,4-dioxo-8-azaspiro[4.5]dec-8-yl or 4-oxooctahydro-1(2H)-quinolinyl,

R⁴ is hydrogen,

R⁵ is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen,
R⁶ is hydrogen, methyl or Cl,
R⁷ is hydrogen, methyl, Br, F or Cl,
and at least one of R⁵, R⁶ or R⁷ is different from hydrogen when R² is hydrogen, R³ is H or 2,6-diisopropylphenyl and R^{3a} is H.


4. (currently amended) A compound according to ~~any of the claims 1 to 3~~ wherein R² is hydrogen or methyl.
5. (currently amended) A compound according to ~~any of the preceding claims 1~~ wherein R³ is hydrogen.
6. (currently amended) A compound according to ~~any of the preceding claims 1~~ wherein R^{3a} is hydrogen.
7. (currently amended) A compound according to ~~any of the preceding claims 1~~ wherein R⁵ is halogen or trifluoromethyl.
8. (currently amended) A compound according to ~~any of the preceding claims 1~~ wherein R⁶ is hydrogen.
9. (currently amended) A compound according to ~~any of the preceding claims 1~~ wherein R⁷ is hydrogen, Br, or F.
10. (currently amended) A compound according to ~~any of the preceding claims 1~~ wherein R² is C₁₋₂₀-alkyl and the carbon atom to which R² is attached is in the "S"-configuration.
11. (original) A compound selected from 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5,7-dibromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-nitro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; (2R)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; (2S)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; 2-[2-oxo-5-(fluoromethoxy)-2,3-dihydro-1H-indol-1-yl]acetamide; 2-(5-isopropyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-ethyl-2-oxo-2,3-dihydro-

1H-indol-1-yl)acetamide; 2-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5,7-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(2-oxo-5-propyl-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(2-oxo-5-(trifluoromethyl)-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5,6-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(7-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(6-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide; (+)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide; (-)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide; 2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; (+)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; (-)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; 2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; (-)-2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; (+)-2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide; 2-(5-chloro-7-fluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxyphenyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-fluorophenyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(2-pyridin-2-ylethyl)phenyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide; 5-chloro-1-[2-oxo-2-(4-pyridin-2-yl)piperzin-1-yl]ethyl]-1,3-dihydro-2H-indol-2-one; 5-chloro-1-{2-[4-(3-methylphenyl)piperzin-1-yl]-2-oxoethyl}-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(4-hydroxy-3-methoxybenzyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N(pyridine-4-ylmethyl)-N-(tetrahydrofuran-2-ylmethyl)acetamide; 5(chloro-1-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N'-isonicotinoylacetohydrazide; 5-chloro-1-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(4H-1,2,4-triazol-3-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[4-(methylsulfonyl)benzyl]acetamide; 1-[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]octahydroquinolin-4(1H)-one; N'-(4-bromophenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetohydrazide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(6-methoxypyridin-3-yl)acetamide; N-butyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)

yl) acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(dimethylamino)propyl]acetamide; 5-chloro-1-{2-oxo-2-[4-(2-phenylethyl)piperazin-1-yl]ethyl}-1,3-dihydro-2H-indol-2-one; ethyl{[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]amino}acetate; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-ethoxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-fluoroethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methoxy-N-methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dimethylphenyl)acetamide; N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxy-2,2-dimethylpropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[1-(hydroxymethyl)propyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-hydroxy-2-phenylethyl) acetamide; 5-chloro-1-{2-[4-(4-hydroxyphenyl)piperazin-1-yl]-2-oxoethyl}-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(pyridin-4-ylmethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[(5-methyl-2-furyl)methyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(1H-pyrazol-1-yl)propyl]acetamide; methyl 3-[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]-1,3-thiazolidine-4-carboxylate; 5-chloro-1-[2-(2,5-dihydro-1H-pyrrol-1-yl)-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N'-(4,5-dihydro-1H-imidazol-2-yl)acetohydrazide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-chlorophenylethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(4-methylphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-morpholin-4-ylethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-methylpiperidin-1-yl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-nitrobenzyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dihydro-1H-isochromen-1-methyl)acetamide; N-(2-chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide; N-benzyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-

yl)-N-methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-{2-[(trifluoromethyl) thio] benzyl}acetamide; 5-chloro-1-[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-cycloheptylacetamide; 5-chloro-1-{2-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]-2-oxoethyl}-1,3-dihydro-2H-indol-2-one; and 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-pyridin-3-ylacetamide.

12. (original) A compound selected from 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide and (2S)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide.
13. (currently amended) A compound having the formula II or stereoisomeric forms thereof,




wherein

R^1 is hydrogen,


R^2 is hydrogen or C_{1-20} -alkyl,

R^3 is hydrogen, C_{1-20} -alkyl, C_{4-8} -cycloalkyl, C_{5-8} -cycloalkylenyl, aryl, aromatic or non aromatic heterocycle, C_{1-20} -alkoxy, or a group of formula- $W-R^8$,

R^{3a} is hydrogen, C_{1-20} -alkyl or a group of formula:



or NR^3R^{3a} is a group of formula



R^4 is hydrogen,

R^5 is hydrogen; nitro; halogen; azido; cyano; $-S-C_{1-4}\text{-alkyl}$; $-SO-C_{1-4}\text{-alkyl}$; $-SO_2-C_{1-4}\text{-alkyl}$; $-SONH_2$; $C_{1-20}\text{-alkyl}$ unsubstituted or substituted by halogen; or $C_{1-20}\text{-alkoxy}$ unsubstituted or substituted by halogen,

R^6 is hydrogen, $C_{1-20}\text{-alkyl}$ or halogen,

R^7 is hydrogen, $C_{1-20}\text{-alkyl}$ or halogen,

W is $C_{1-12}\text{-alkylene}$, $-NH-$ or $-NHC(=O)-$,

X is O, S or NH,

Y is O, S, $-CR^{12}R^{13}-$, $-NR^{14}-$ or $-C(=O)-$,

R^8 is aryl or heterocycle,

R^9 , R^{10} , R^{10a} and R^{11} are independently selected from hydrogen, $C_{1-4}\text{-alkyl}$, halogen, hydroxy or methoxycarbonyl,

or R^{10} and R^{10a} together form a $C_{3-6}\text{-alkylene}$,

R^{12} is hydrogen, $C_{1-4}\text{-alkyl}$, halogen or hydroxy,

R^{13} is hydrogen, or $CR^{12}R^{13}$ is dioxolanyl,

R^{14} is aryl, heterocycle or a group of formula-V- R^{15} ,

V is $C_{1-12}\text{-alkylene}$,


R^{15} is aryl or heterocycle,

m is 1 to 4,

n is 0 or 1,

and at least one of R^5 , R^6 or R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2,6-diisopropylphenyl, and R^{3a} is H.

14. (currently amended) A compound having the formula III or stereoisomeric forms thereof,




wherein

R^4 is hydrogen,

R^5 is hydrogen; nitro; azido; cyano; $-S-C_{1-4}\text{-alkyl}$; $-SO-C_{1-4}\text{-alkyl}$; $-SO_2-C_{1-4}\text{-alkyl}$; $-SONH_2$; $C_{1-20}\text{-alkyl}$ unsubstituted or substituted by halogen; or $C_{1-20}\text{-alkoxy}$ unsubstituted or substituted by halogen,

R^6 is hydrogen, C_{1-20} -alkyl or halogen,
 R^7 is hydrogen, C_{1-20} -alkyl or halogen,
 and at least one of R^5 , R^6 ~~or~~ and R^7 is different from hydrogen.

15. (currently amended) A compound having the formula VI or stereoisomeric forms thereof,




wherein

R^1 is hydrogen,


R^2 is hydrogen or C_{1-20} -alkyl,

R^3 is hydrogen, C_{1-20} -alkyl, C_{4-8} -cycloalkyl, C_{5-8} -cycloalkylenyl, aryl, aromatic or non-aromatic heterocycle, C_{1-20} -alkoxy, or a group of formula $-W-R^8$,

R^{3a} is hydrogen, C_{1-20} -alkyl or a group of formula:



or NR^3R^{3a} is a group of formula:



R^4 is hydrogen,

R^5 is hydrogen; halogen; azido; cyano; $-S-C_{1-4}$ -alkyl; $-SO-C_{1-4}$ -alkyl; $-SO_2-C_{1-4}$ -alkyl; $-SONH_2$; or C_{1-20} -alkyl unsubstituted or substituted by halogen,

R^6 is hydrogen, C_{1-20} -alkyl or halogen,

R^7 is hydrogen, C_{2-20} -alkyl or halogen,

W is C_{1-12} -alkylene, $-NH-$ or $-NHC(=O)-$,

X is O, S or NH,

Y is O, S, $-\text{CR}^{12}\text{R}^{13}-$, NR^{14} or $-\text{C}(=\text{O})-$

R^8 is aryl or heterocycle,

R^9 , R^{10} , R^{10a} and R^{11} are independently selected from hydrogen, C_{1-4} -alkyl, halogen, hydroxy or methoxycarbonyl,

or R^{10} and R^{10a} together form a C_{3-6} -alkylene,

R^{12} is hydrogen, C_{1-4} -alkyl, halogen or hydroxy,

R^{13} is hydrogen, or $\text{CR}^{12}\text{R}^{13}$ is dioxolanyl,

R^{14} is aryl, heterocycle or a group of formula $-\text{V}-\text{R}^{15}$,

V is C_{1-12} -alkylene,


R^{15} is aryl or heterocycle,

m is 1 to 4,

n is 0 or 1,

and at least one of R^5 , R^6 ~~or~~ and R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2,6-diisopropylphenyl, and R^{3a} is H.

16. (currently amended) A compound having the formula IX or stereoisomeric forms thereof,



wherein

R^1 is hydrogen,

R^2 is hydrogen or C_{1-20} -alkyl,

R^4 is hydrogen,

R^5 is hydrogen; nitro; azido; cyano; $-\text{S}-\text{C}_{1-4}$ -alkyl; $-\text{SO}-\text{C}_{1-4}$ -alkyl; $-\text{SO}_2-\text{C}_{1-4}$ -alkyl;

$-\text{SONH}_2$; halogen; C_{1-20} -alkyl unsubstituted or substituted by halogen; or C_{1-20} -alkoxy unsubstituted or substituted by halogen,

R^6 is hydrogen or C_{1-20} -alkyl,

R^7 is hydrogen, C_{1-20} -alkyl or halogen,

and at least one of R^5 , R^6 ~~or~~ and R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2,6-diisopropylphenyl, and R^{3a} is H.

17. (original) A compound which is selected from the group consisting of:
- 2-(5'-methyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;
 - 2-[2'-oxo-5'-[(trifluoromethyl)oxy]spiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl]acetamide;
 - 2-[5'-(1-methylethyl)-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl]acetamide;
 - 2-(5'-ethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;
 - 2-(5'-fluoro-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;
 - 2-(5',7'-dimethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1')acetamide;
 - 2-(2'-oxo-5'-propylspiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;
 - 2-[2'-oxo-5'-(trifluoromethyl)spiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl]acetamide;
 - 2-(5',6'-dimethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;
 - 5'-methylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5'-[(trifluoromethyl)oxy]spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one; 5'-(1-methylethyl)spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5'-ethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5'-fluorospiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5',7'-dimethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5'-propylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5'-(trifluoromethyl)spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 5',6'-dimethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
 - 2-(5-chloro-1H-indol-1-yl)propanamide;
 - 2-(7-chloro-1H-indol-1-yl)acetamide;
 - 2-(6-chloro-1H-indol-1-yl)acetamide;
 - 2-(5-chloro-1H-indol-1-yl)butanamide;
 - 2-(5-methyl-1H-indol-1-yl)propanamide;
 - 2-(5-bromo-1H-indol-1-yl)propanamide;
 - 2-(7-fluoro-1H-indol-1-yl)acetamide;
 - 2-(5-bromo-1H-indol-1-yl)acetamide;
 - 2-(5-fluoro-1H-indol-1-yl)acetamide;
 - 2-(5-chloro-1H-indol-1-yl)acetamide;
 - (5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetic acid.

18. (currently amended) A pharmaceutical composition comprising an effective amount of a compound according to ~~any of claims 1 to 12~~ in combination with a pharmaceutically acceptable diluent or carrier.
19. (currently amended) A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions, Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by administration of neuroleptic drugs, Huntington Chorea, and other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactivity disorder (ADHD), migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis, in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound according to ~~any of Claims 1-12 or a pharmaceutical composition according to claim 18.~~
20. (canceled)
21. (canceled)